Related Experiment Video
Updated: Jan 9, 2026

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds
Published on: February 14, 2018
Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent
Marisa H Miceli1, Carol A Kauffman2
1Division of Infectious Diseases, Department of Internal Medicine, University of Michigan Health System.
Abstract:
Isavuconazole is a new extended-spectrum triazole with activity against yeasts, molds, and dimorphic fungi. It is approved for the treatment of invasive aspergillosis and mucormycosis. Advantages of this triazole include the availability of a water-soluble intravenous formulation, excellent bioavailability of the oral formulation, and predictable pharmacokinetics in adults. A randomized, double-blind comparison clinical trial for treatment of invasive aspergillosis found that the efficacy of isavuconazole was noninferior to that of voriconazole. An open-label trial that studied primary as well as salvage therapy of invasive mucormycosis showed efficacy with isavuconazole that was similar to that reported for amphotericin B and posaconazole. In patients in these studies, as well as in normal volunteers, isavuconazole was well tolerated, appeared to have few serious adverse effects, and had fewer drug-drug interactions than those noted with voriconazole. As clinical experience increases, the role of this new triazole in the treatment of invasive fungal infections will be better defined.
Insights
Isavuconazole is a new antifungal medication effective against various fungi, including invasive aspergillosis and mucormycosis. Clinical trials show it is as effective as voriconazole and well-tolerated with fewer drug interactions.
Area of Science:
- Mycology
- Infectious Diseases
- Pharmacology
Background:
- Isavuconazole is an extended-spectrum triazole antifungal agent.
- It demonstrates activity against yeasts, molds, and dimorphic fungi.
- Approved for invasive aspergillosis and mucormycosis treatment.
Purpose of the Study:
- To evaluate the efficacy and safety of isavuconazole.
- Compare isavuconazole with voriconazole for invasive aspergillosis.
- Assess isavuconazole in invasive mucormycosis treatment.
Main Methods:
- Randomized, double-blind clinical trial for invasive aspergillosis.
- Open-label trial for invasive mucormycosis (primary and salvage therapy).
- Pharmacokinetic and safety assessments in patients and volunteers.
Main Results:
- Isavuconazole demonstrated non-inferior efficacy to voriconazole in invasive aspergillosis.
- Efficacy in invasive mucormycosis was similar to amphotericin B and posaconazole.
- Isavuconazole was well-tolerated with a favorable safety profile and fewer drug-drug interactions.
Conclusions:
- Isavuconazole is an effective and well-tolerated treatment option for invasive aspergillosis and mucormycosis.
- Its predictable pharmacokinetics and favorable drug interaction profile are advantageous.
- Further clinical experience will define its role in treating invasive fungal infections.
More Related Videos
12:29Live Imaging of Antifungal Activity by Human Primary Neutrophils and Monocytes in Response to A. fumigatus
Published on: April 19, 2017
06:49Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians
Published on: March 14, 2014
Related Concept Videos
Fungal Phylum Ascomycota
Antimicrobial Effectiveness
Fungal Phylum Microsporidia
Fungal Group Zygomycota
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers